Company Overview

Insmed Incorporated is a global biopharmaceutical company dedicated to developing and commercializing therapies for patients with serious and rare diseases. The company operates in the United States, Europe, Japan, and internationally. Founded in 1988 and headquartered in Bridgewater, New Jersey, Insmed trades on the NASDAQ under the ticker symbol INSM.

Insmed is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines, alongside its drug discovery efforts. Its advanced programs focus on pulmonary and inflammatory conditions, including a therapy already approved in the United States, Europe, and Japan for a chronic, debilitating lung disease. Despite a challenging biotech market, Insmed entered 2025 with over $1.4 billion in cash, continues to achieve double-digit growth for its commercial product, anticipates several significant clinical readouts within the next 12 months, and is preparing for a highly anticipated drug launch later this year, pending FDA approval.

Core Products and Pipeline

Insmed's therapeutic focus is on creating innovative treatments for unmet medical needs in rare diseases, particularly in pulmonary and inflammatory conditions.

ARIKAYCE - Commercial Success

ARIKAYCE is approved for the treatment of refractory nontuberculous mycobacterial (NTM) lung infections. It is also undergoing Phase 3 clinical trials for the treatment of Mycobacterium avium complex (MAC) lung disease, as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

Global revenue for ARIKAYCE grew by 19% in 2024 compared to 2023, driven by strong performance in the U.S., Japan, and Europe. Insmed projects full-year 2025 global ARIKAYCE revenues to be between $405 million and $425 million, representing an 11% to 17% year-over-year growth from 2024.

Brensocatib - Breakthrough Treatment

Brensocatib is an oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1). It is currently in Phase 3 clinical trials for the treatment of bronchiectasis and other neutrophil-mediated diseases, including chronic rhinosinusitis without nasal polyps (CRSsNP).

In February 2025, the FDA accepted Insmed's New Drug Application (NDA) for brensocatib for patients with bronchiectasis, granting it Priority Review with a target action date of August 12, 2025. On Tuesday, the U.S. Food and Drug Administration approved Insmed Incorporated's INSM Brinsupri (brensocatib 10 mg and 25 mg tablets), marking the first approved oral treatment for this chronic lung disease.

TPIP - Pulmonary Hypertension Treatment

Treprostinil palmitil inhalation powder (TPIP) is an inhaled formulation of a treprostinil prodrug. It is in Phase 3 clinical trials for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH), offering a differentiated product profile.

Insmed achieved positive Phase 2b results for TPIP in PAH, meeting all endpoints and paving the way for Phase 3 trials in 2025-2026.

Gene Therapy Programs

Insmed is also developing gene therapy solutions. This includes a micro-dystrophin adeno-associated virus gene replacement therapy currently in Phase 1 clinical trials for Duchenne muscular dystrophy. Further gene therapy candidates targeting amyotrophic lateral sclerosis (ALS) and Stargardt disease are advancing toward the clinic.

In addition to gene therapy, Insmed's pre-clinical development includes programs for a next-generation DPP1 inhibitor, de-immunized therapeutic proteins, and synthetic rescue strategies. The company has over 30 identified pre-clinical programs with the potential to become first-in-class or best-in-class therapies. Insmed anticipates submitting an average of one to two Investigational New Drug (IND) applications per year from its pre-clinical research program.

Financial Performance

Insmed maintains a strong financial footing, supporting its extensive research and development efforts and commercialization of its rare disease therapies.

Revenue Growth

- Q1 2025 Revenue: $0.093 billion (22.94% year-over-year increase)

- Trailing Twelve Months (TTM) Revenue (as of March 2025): $0.381 billion (20.77% year-over-year increase)

- 2024 Annual Revenue: $0.364 billion (19.17% increase from 2023)

Balance Sheet Strength

- Cash Position (as of December 31, 2024): Approximately $1.4 billion in cash, cash equivalents, and marketable securities.

Market Capitalization

- Market Cap (as of September 08, 2025): $30.67 billion

Key Financial Metrics

- Revenue (TTM as of March 2025): $0.381 billion

- 2024 Annual Revenue: $0.364 billion

- Cash Position (Dec 2024): $1.4 billion

- Market Cap (Sep 2025): $30.67 billion

- Employees (Sep 2025): 1,270

Clinical Milestones and Regulatory Progress

Insmed has achieved significant progress in clinical trials and regulatory submissions, highlighting its commitment to bringing novel treatments to patients.

- Phase 3 ENCORE Study (ARIKAYCE): In Q4 2024, the company completed enrollment for the Phase 3 ENCORE study evaluating ARIKAYCE in newly diagnosed or recurrent MAC lung disease. The study enrolled 425 patients. A topline readout is anticipated in Q1 2026, followed by an sNDA submission to the FDA for ARIKAYCE in all MAC lung disease patients in the U.S. later in 2026.

- Brensocatib Approval: The FDA approved Insmed's oral drug, brensocatib (INSM Brinsupri), for bronchiectasis, making it the first treatment for this chronic condition. The NDA received Priority Review with an August 12, 2025, target action date.

Investment Profile

Insmed Incorporated (NASDAQ: INSM) does not currently pay dividends, as the company prioritizes reinvesting earnings into research and development to expand its pipeline of rare disease treatments.

2024 was a landmark year for Insmed, marked by significant achievements and advancements that reinforced its position as a leading biotechnology company. Key successes included positive topline results from the Phase 3 ASPEN study of brensocatib in patients with bronchiectasis.

With a robust pipeline across multiple therapeutic areas, a strong financial position, and recent regulatory approvals, Insmed is well-positioned as a leader in developing treatments for patients with serious and rare diseases. The company's strategic focus on pulmonary conditions, inflammatory diseases, and gene therapy addresses significant market opportunities within underserved patient populations.